5 / 85
[
]5
Acknowledgements . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
3
Foreword by Jacqui Griffiths . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
4
Influenza pandemic: overcoming global issues . . . . . . . . . . . . . .8
David Nabarro, UN System Influenza Coordinator for Avian and Human
Influenza (UNSIC), and Iain Bald, UN Office for the Coordination of
Humanitarian Affairs (OCHA)
Limiting the impact of pandemic influenza through
community-level actions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .12
Jim Catampongan, Avian and Human Influenza Coordinator, Asia and
Pacific, International Federation of Red Cross and Red Crescent Societies
Influenza: how to blunt the Damocletian sword . . . . . . . . . . . .16
Professor Albert Osterhaus, DVM, PhD, Head, Department of Virology,
Erasmus MC, Rotterdam
Preparing for the next influenza pandemic . . . . . . . . . . . . . . . .19
Steve Redd, US Centers for Disease Control and Prevention
Cell culture (Vero) derived pandemic influenza vaccines . . . . . .23
P. Noel Barrett, Baxter Bioscience, Biomedical Research Centre,
Orth/Donau and Hartmut J. Ehrlich, Baxter Bioscience, Vienna
Australian aid programme initiatives to combat
emerging infectious diseases . . . . . . . . . . . . . . . . . . . . . . . . . . .26
Australian Agency for International Development
Thwarting the secondary enemy . . . . . . . . . . . . . . . . . . . . . . . .30
Hassan Ahmad and Siti Sayadi, Mercy Relief, Singapore
European Medicines Agency: influenza pandemic preparedness . .36
Ragini Shivji, Scientific Administrator and John Purves, Head of Sector,
Quality of Medicines Sector, EMEA; and Patrick Celis, Principal Scientific
Administrator, Regulatory Affairs and Organizational Support Sector, EMEA
Contents
12
30
16
36